Laboratory Medicine, University Hospital of North Norway, N-9038 Tromsø, Norway.
Expert Rev Hematol. 2010 Oct;3(5):559-66. doi: 10.1586/ehm.10.49.
Uncertainty regarding the pathophysiology of fetal and neonatal alloimmune thrombocytopenia (FNAIT) has hampered the decision regarding how to identify, follow-up and treat the women and children with this potentially serious condition. Since knowledge of the condition is derived mainly from retrospective studies, understanding of the natural history of this condition remains incomplete. General screening programs for FNAIT have still not been introduced, mainly because of a lack of reliable risk factors and effective treatment. Now, several prospective screening studies involving up to 100,000 pregnant women have been published and the results have changed the understanding of the pathophysiology of FNAIT and, thereby, the approach toward diagnostics, prevention and treatment in a more appropriate way.
胎儿和新生儿同种免疫性血小板减少症（FNAIT）的发病机制尚不确定，这使得如何识别、随访和治疗这种潜在严重疾病的妇女和儿童的决策受到阻碍。由于对该疾病的认识主要来自回顾性研究，因此对该疾病的自然病程仍不完全了解。由于缺乏可靠的危险因素和有效的治疗方法，一般的 FNAIT 筛查计划尚未推出。目前，已经发表了几项涉及多达 100,000 名孕妇的前瞻性筛查研究，这些结果改变了对 FNAIT 发病机制的认识，并因此以更恰当的方式改变了对诊断、预防和治疗的方法。
